The Law Firm of Levi & Korsinsky, LLP Announces Investigation into Possible Breaches of Fiduciary Duty by the Board of Gen-Probe Incorporated in Connection with the Sale of the Company to Hologic, Inc.

NEW YORK--(BUSINESS WIRE)--Levi & Korsinsky is investigating the Board of Directors of Gen-Probe Incorporated (“Gen-Probe” or the “Company”) (Nasdaq: GPRO) for possible breaches of fiduciary duty and other violations of state law in connection with the sale of the Company to Hologic, Inc. (Nasdaq: HOLX). Under the terms of the agreement, Gen-Probe shareholders will receive $82.75 for each share of Gen-Probe stock they own. The transaction has a total approximate value of $3.7 billion.

Click here to learn how to join the action: http://www.zlk.com/gen-probe-gpro, or call: 877-363-5972. There is no cost or obligation to you.

The investigation concerns whether the Gen-Probe Board of Directors breached their fiduciary duties to Gen-Probe stockholders by failing to adequately shop the Company before entering into this transaction and whether Hologic, Inc. is underpaying for Gen-Probe shares, thus unlawfully harming Gen-Probe stockholders.

If you own common stock in Gen-Probe and wish to obtain additional information, please contact Joseph E. Levi, Esq. either via email at [e-mail] or by telephone at [phone], toll-free: [phone], or http://www.zlk.com.

Levi & Korsinsky is a national firm with offices in New York and Washington D.C. The firm has extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. The attorneys at Levi & Korsinsky have been appointed by numerous courts throughout the country to serve as lead counsel on behalf of shareholders in major securities lawsuits and have successfully recovered multimillion-dollar damages awards on behalf of investors. For more information, please feel free to contact any of the attorneys listed below. Attorney advertising. Prior results do not guarantee similar outcomes.